Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/137415
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWright, L.-
dc.contributor.authorBarnes, T.J.-
dc.contributor.authorPrestidge, C.A.-
dc.date.issued2020-
dc.identifier.citationInternational Journal of Pharmaceutics, 2020; 585:119488-1-119488-17-
dc.identifier.issn0378-5173-
dc.identifier.issn1873-3476-
dc.identifier.urihttps://hdl.handle.net/2440/137415-
dc.description.abstractThe number of biological molecules emerging as therapeutics is growing exponentially due to their higher specificity and tolerability profiles compared to small molecules. Despite this, their traditionally parenteral delivery often results in poor patient compliance and incomplete treatment. Current research is focussed on developing effective oral delivery strategies to facilitate administration of these biomolecules, however no universal method exists to simultaneously provide gastric protection as well as enhance transport across the gastrointestinal epithelium. Furthermore, for efficient formulation development it is imperative that we can reliably analyse permeability of biomolecules through the gastrointestinal tract, highlighting the importance of the continual development and ongoing evaluation of in vitro predictive permeability tools. Here, we review the physiological obstacles associated with peptide and protein delivery throughout the gastrointestinal tract. Furthermore, we highlight methods utilised to circumvent these barriers and promote improved intestinal permeability. Lastly, we explore in vitro models employed to predict epithelial transport. Key findings highlight the need to carefully understand gastrointestinal physiology, allowing specific engineering of oral delivery systems for biomolecules. Significant importance is placed upon understanding enzymatic degradation susceptibility as well as uptake mechanisms for particulate and protein-based therapeutics for the development of successful oral protein delivery platforms.-
dc.description.statementofresponsibilityLeah Wright, Timothy J. Barnes, Clive A. Prestidge-
dc.language.isoen-
dc.publisherElsevier-
dc.rights© 2020 Elsevier B.V. All rights reserved-
dc.source.urihttp://dx.doi.org/10.1016/j.ijpharm.2020.119488-
dc.subjectOral; Protein; Peptide; Drug delivery; Permeability; Nanoparticle; Formulation-
dc.subject.meshGastrointestinal Tract-
dc.subject.meshCell Line-
dc.subject.meshAnimals-
dc.subject.meshHumans-
dc.subject.meshProteins-
dc.subject.meshBiological Factors-
dc.subject.meshDrug Delivery Systems-
dc.subject.meshAdministration, Oral-
dc.subject.meshPermeability-
dc.subject.meshForecasting-
dc.subject.meshGlucagon-Like Peptide 1-
dc.subject.meshGastric Absorption-
dc.titleOral delivery of protein-based therapeutics: Gastroprotective strategies, physiological barriers and in vitro permeability prediction-
dc.typeJournal article-
dc.identifier.doi10.1016/j.ijpharm.2020.119488-
dc.relation.grantARC-
pubs.publication-statusPublished-
dc.identifier.orcidWright, L. [0000-0001-8796-0669]-
Appears in Collections:Chemical Engineering publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.